Preclinical HER-2 vaccines: from rodent to human HER-2
Effective prevention of human cancer with vaccines against viruses, such as HBV and HPV, raises the question whether also non-virus related tumors could be prevented with immunological means. Studies in HER-2-transgenic mice showed that powerful anti-HER-2 vaccines, could almost completely prevent...
Main Authors: | Pier-Luigi eLollini, Carla eDe Giovanni, Patrizia eNanni |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2013-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00151/full |
Similar Items
-
Cancer immunoprevention: from mice to early clinical trials
by: Arianna Palladini, et al.
Published: (2018-06-01) -
Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans
by: Marco Macagno, et al.
Published: (2011-08-01) -
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
by: Carla De Giovanni, et al.
Published: (2021-07-01) -
Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer
by: Sylwia Dębska-Szmich, et al.
Published: (2015-05-01) -
Tailoring DNA vaccines: designing strategies against HER2 positive cancers
by: Cristina eMarchini, et al.
Published: (2013-05-01)